Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
Entera Bio announced that post-hoc Phase 2 data for its oral anabolic tablet EB613 has been selected for a Plenary Poster Presentation at the ASBMR 2026 Annual Meeting. The analysis of 161 patients demonstrated markedly enhanced anabolic effects in postmenopausal women with osteoporosis at high risk for fracture, defined by a baseline T-score of ≤-2.5.
Key figures
- Drug Name
- EB613 (oral PTH(1-34))
- Phase Of Trial
- Phase 2
- Baseline t score
- ≤-2.5
- Phase 2 patient count
- 161
- Plenary presentations
- 2
- Planned phase 3 patient count
- 750
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.